- Record: found
- Abstract: not found
- Article: not found
Transient Asymptomatic Pulmonary Opacities Occurring during Osimertinib Treatment
December 2016
December 2016
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Osimertinib is an EGFR inhibitor licensed for the treatment of EGFR-mutant, T790M-positive
NSCLC. Previously unreported, frequent transient asymptomatic pulmonary opacities
were noted in patients during osimertinib therapy at the University of Colorado.